11
Participants
Start Date
October 3, 2023
Primary Completion Date
September 25, 2024
Study Completion Date
September 25, 2024
177Lu-LNC1004 Injection group 1 radionuclide therapy
The treatment regimen will consist of a single dose 30mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
177Lu-LNC1004 Injection group 2 radionuclide therapy
The treatment regimen will consist of a single dose 60mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
177Lu-LNC1004 Injection group 3 radionuclide therapy
The treatment regimen will consist of a single dose 80mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
177Lu-LNC1004 Injection group 4 radionuclide therapy
The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
National University Cancer Institute, Singapore National University Hospital, Singapore., Singapore
Yantai LNC Biotechnology Singapore PTE. LTD.
INDUSTRY